Literature DB >> 34137074

Concurrent axon and myelin destruction differentiates X-linked adrenoleukodystrophy from multiple sclerosis.

Caroline G Bergner1,2, Nafiye Genc1, Simon Hametner3, Jonas Franz1,4,5, Franziska van der Meer1, Miso Mitkovski6, Martin S Weber2, Gisela Stoltenburg-Didinger7, Jörn-Sven Kühl8, Wolfgang Köhler9, Wolfgang Brück1, Jutta Gärtner10, Christine Stadelmann1.   

Abstract

Cerebral disease manifestation occurs in about two thirds of males with X-linked adrenoleukodystrophy (CALD) and is fatally progressive if left untreated. Early histopathologic studies categorized CALD as an inflammatory demyelinating disease, which led to repeated comparisons to multiple sclerosis (MS). The aim of this study was to revisit the relationship between axonal damage and myelin loss in CALD. We applied novel immunohistochemical tools to investigate axonal damage, myelin loss and myelin repair in autopsy brain tissue of eight CALD and 25 MS patients. We found extensive and severe acute axonal damage in CALD already in prelesional areas defined by microglia loss and relative myelin preservation. In contrast to MS, we did not observe selective phagocytosis of myelin, but a concomitant decay of the entire axon-myelin unit in all CALD lesion stages. Using a novel marker protein for actively remyelinating oligodendrocytes, breast carcinoma-amplified sequence (BCAS) 1, we show that repair pathways are activated in oligodendrocytes in CALD. Regenerating cells, however, were affected by the ongoing disease process. We provide evidence that-in contrast to MS-selective myelin phagocytosis is not characteristic of CALD. On the contrary, our data indicate that acute axonal injury and permanent axonal loss are thus far underestimated features of the disease that must come into focus in our search for biomarkers and novel therapeutic approaches.
© 2021 The Authors. GLIA published by Wiley Periodicals LLC.

Entities:  

Keywords:  X-linked adrenoleukodystrophy; axonal injury; demyelination; multiple sclerosis; remyelination

Mesh:

Year:  2021        PMID: 34137074     DOI: 10.1002/glia.24042

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  1 in total

1.  Targeted Brain Delivery of Dendrimer-4-Phenylbutyrate Ameliorates Neurological Deficits in a Long-Term ABCD1-Deficient Mouse Model of X-Linked Adrenoleukodystrophy.

Authors:  Christina L Nemeth; Özgül Gӧk; Sophia N Tomlinson; Anjali Sharma; Ann B Moser; Sujatha Kannan; Rangaramanujam M Kannan; Ali Fatemi
Journal:  Neurotherapeutics       Date:  2022-10-07       Impact factor: 6.088

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.